Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15

Chemical Biology and Drug Design

Volumn 86, Issue 5, 2015, Pages 1036-1048

  Wang, Xin ^a   D'Arcy, Pádraig ^a   Caulfield, Thomas R ^b   Paulus, Aneel ^b   Chitta, Kasyapa ^b   Mohanty, Chitralekha ^c   Gullbo, Joachim ^d   Chanan Khan, Asher ^b   Linder, Stig ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b MAYO CLINIC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

chalcone; deubiquitinase; in silico modeling; inhibitor; lead optimization; proteasome

Indexed keywords

ACETAMIDE; ANTINEOPLASTIC AGENT; B AP 15; CASPASE 3; CHALCONE DERIVATIVE; POLYUBIQUITIN; PROTEASOME; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VLX 1570; DEUBIQUITINASE; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; COMPETITIVE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; COVALENT BOND; DEFLUORINATION; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; ELECTROPHILICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HCT116 CELL LINE; HUMAN; HUMAN CELL; HYDROGENATION; IN VITRO STUDY; LIVER CELL; MALE; MICHAEL ADDITION; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULAR DOCKING; SPRAGUE DAWLEY RAT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHALCONES; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; PROTEASOME INHIBITORS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84944164063     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12571     Document Type: Article

References (45)

1. Hershko A., Ciechanover A., (1998) The ubiquitin system. Annu Rev Biochem; 67: 425-479.
2. Groll M., Ditzel L., Lowe J., Stock D., Bochtler M., Bartunik H.D., Huber R., (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature; 386: 463-471.
3. Komander D., Clague M.J., Urbe S., (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol; 10: 550-563.
4. D'Arcy P., Wang X., Linder S., (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther; 147: 32-54.
5. D'Arcy P., Linder S., (2014) Molecular pathways: translational potential of deubiquitinases as drug targets. Clin Cancer Res; 20: 3908-3914.
6. Adams J., (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell; 5: 417-421.
7. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., et al,. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med; 352: 2487-2498.
8. D'Arcy P., Brnjic S., Olofsson M.H., Fryknäs M., Lindsten K., De Cesare M., Perego P., Sadeghi B., Hassan M., Larsson R., Linder S., (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med; 17: 1636-1640.
9. Tian Z., D'Arcy P., Wang X., Ray A., Tai Y.T., Hu Y., Carrasco R.D., Richardson P., Linder S., Chauhan D., Anderson K.C., (2013) A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood; 125: 706-716.
10. Coughlin K., Anchoori R., Iizuka Y., Meints J., MacNeill L., Vogel R.I., Orlowski R.Z., Lee M.K., Roden R.B., Bazzaro M., (2014) Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res; 20: 3174-3186.
11. Zhou B., Zuo Y., Li B., Wang H., Liu H., Wang X., et al,. (2013) Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells. Mol Cancer Ther; 12: 1381-1392.
12. Menendez-Benito V., Verhoef L.G., Masucci M.G., Dantuma N.P., (2005) Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet; 14: 2787-2799.
13. Lindhagen E., Nygren P., Larsson R., (2008) The fluorometric microculture cytotoxicity assay. Nat Protoc; 3: 1364-1369.
14. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R., (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res; 48: 589-601.
15. Mohamadi F., Richard N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., Still W.C., (1990) Macromodel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem; 11: 440-467.
16. Jorgensen W.L., Tiradorives J., (1988) The opls potential functions for proteins-energy minimizations for crystals of cyclic-peptides and crambin. J Am Chem Soc; 110: 1657-1666.
17. Caulfield T., Devkota B., (2012) Motion of transfer RNA from the A/T state into the A-site using docking and simulations. Proteins; 80: 2489-2500.
18. Loving K., Salam N.K., Sherman W., (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des; 23: 541-554.
19. Vivoli M., Caulfield T.R., Martinez-Mayorga K., Johnson A.T., Jiao G.S., Lindberg I., (2012) Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives. Mol Pharmacol; 81: 440-454.
20. Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz D.T., (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem; 49: 6177-6196.
21. Hu M., Li P., Song L., Jeffrey P.D., Chenova T.A., Wilkinson K.D., Cohen R.E., Shi Y., (2005) Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J; 24: 3747-3756.
22. Burgie S.E., Bingman C.A., Soni A.B., Phillips G.N. Jr, (2012) Structural characterization of human Uch37. Proteins; 80: 649-654.
23. Salam N.K., Nuti R., Sherman W., (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model; 49: 2356-2368.
24. Caulfield T., Medina-Franco J.L., (2011) Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A. J Struct Biol; 176: 185-191.
25. Wang X., Stafford W., Mazurkiewicz M., Fryknäs M., Brjnic S., Zhang X., Gullbo J., Larsson R., Arner E.S., D'Arcy P., Linder S., (2014) The 19S deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. Mol Pharmacol; 85: 932-945.
26. Dearfield K.L., Douglas G.R., Ehling U.H., Moore M.M., Sega G.A., Brusick D.J., (1995) Acrylamide: a review of its genotoxicity and an assessment of heritable genetic risk. Mutat Res; 330: 71-99.
27. Mullally J.E., Moos P.J., Edes K., Fitzpatrick F.A., (2001) Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem; 276: 30366-30373.
28. Liu J.D., Tsai S.H., Lin S.Y., Ho Y.S., Hung L.F., Pan S., Ho F.M., Lin C.M., Liang Y.C., (2004) Thiol antioxidant and thiol-reducing agents attenuate 15-deoxy-delta 12,14-prostaglandin J2-induced heme oxygenase-1 expression. Life Sci; 74: 2451-2463.
29. Kapuria V., Peterson L.F., Fang D., Bornmann W.G., Talpaz M., Donato N.J., (2010) Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res; 70: 9265-9276.
30. Brnjic S., Mazurkiewicz M., Fryknäs M., Sun C., Zhang X., Larsson R., D'Arcy P., Linder S., (2014) Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxid Redox Signal; 21: 2271-2285.
31. Fribley A., Wang C.Y., (2006) Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther; 5: 745-748.
32. Fribley A., Zeng Q., Wang C.Y., (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol; 24: 9695-9704.
33. Ling Y.H., Liebes L., Zou Y., Perez-Soler R., (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem; 278: 33714-33723.
34. Hamamura R.S., Ohyashiki J.H., Kurashina R., Kobayashi C., Zhang Y., Takaku T., Ohyashiki K., (2007) Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer; 97: 1099-1105.
35. Lee B.H., Lee M.J., Park S., Oh D.C., Elsasser S., Chen P.C., Gartner C., Dimova N., Hanna J., Gygi S.P., Wilson S.M., King R.W., Finley D., (2010) Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature; 467: 179-184.
36. Schwickart M., Huang X., Lill J.R., Liu J., Ferrando R., French D.M., Maecker H., O'Rourke K., Bazan F., Eastham-Anderson J., Yue P., Dornan D., Huang D.C., Dixit V.M., (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature; 463: 103-107.
37. Hennenfent K.L., Govindan R., (2006) Novel formulations of taxanes: a review. Old wine in a new bottle?. Ann Oncol; 17: 735-749.
38. Issaenko O.A., Amerik A.Y., (2012) Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. Cell Cycle; 11: 1804-1817.
39. Aleo E., Henderson C.J., Fontanini A., Solazzo B., Brancolini C., (2006) Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res; 66: 9235-9244.
40. Nicholson B., Leach C.A., Goldenberg S.J., Francis D.M., Kodrasov M.P., Tian X., Shanks J., Sterner D.E., Bernal A., Mattern M.R., Wilkinson K.D., Butt T.R., (2008) Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci; 17: 1035-1043.
41. Tsutsui T., Hesabi B., Moons D.S., Pandolfi P.P., Hansel K.S., Koff A., Kiyokawa H., (1999) Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol; 19: 7011-7019.
42. Rane S.G., Dubus P., Mettus R.V., Galbreath E.J., Boden G., Reddy E.P., Barbacid M., (1999) Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet; 22: 44-52.
43. Weerapana E., Wang C., Simon G.M., Richter F., Khare S., Dillon M.B., Bachovchin D.A., Mowen K., Baker D., Cravatt B.F., (2010) Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature; 468: 790-795.
44. Codreanu S.G., Ullery J.C., Zhu J., Tallman K.A., Beavers W.N., Porter N.A., Marnett L.J., Zhang B., Liebler D.C., (2014) Alkylation damage by lipid electrophiles targets functional protein systems. Mol Cell Proteomics; 13: 849-859.
45. Tajc S.G., Tolbert B.S., Basavappa R., Miller B.L., (2004) Direct determination of thiol pKa by isothermal titration microcalorimetry. J Am Chem Soc; 126: 10508-10509.